The effect of SGLT2i on improving cardiovascular health in patients with CVD, with or without type 2 diabetes mellitus, is a combination of multiple mechanisms, including promoting vascular endothelial regeneration and enhancing liver erythropoietin production function and renal filtration. This evidence concerns the gene EPO and diabetes mellitus.